KinaseDetect organizes a workshop on "Drug Discovery" for PhD students as part of the Marie-Curie Initial Training Network ISOLATE, download program here , Odense, Denmark, May 15, 2014.
KinaseDetect presents two Posters at the 7th International Conference on Protein Kinase CK2, in Lublin, Poland, September 2013 Download: Minia et al. and Raaf et al.
KinaseDetect adds KINASERA´s CK2-Fluo Assay Kit to its portfolio, December 11, 2012
KinaseDetect participates in the Marie Curie Initial Training Network ISOLATE, 2012-2015
Formation of KINOMED partnership to accelerate human protein kinase drug discovery, read article in Pharma February 2011
KinaseDetect gets funded by the European Union Eurostars program
KinaseDetect sponsors the Minisymposium on "Protein Kinase CK2", at SDU, in Odense, Denmark, March 7, 2011
KinaseDetect ApS, one of the Life Science companies in Odense, read article in Pharma November 2010
KinaseDetect sponsors the 6th International Conference on Protein Kinase CK2 "Protein Kinase CK2: a catalyst for biology, medicine and structural biology, in Cologne, Germany, September 7 - 10, 2010
Kinase Detect is a biotech company focused on protein kinases and protein kinase related products and services, like kinase inhibitors. The company provides highly purified recombinant human protein kinases. Additional services include protein kinase substrates, protein kinase assays and kinase inhibitors. KinaseDetect was founded in 2001. Since 2002, recombinant protein kinases are sold to (i) academic customers through distributors in USA, Germany, France and Japan and (ii) directly to major pharmaceutical companies. Furthermore, kinase assays are offered as service to pharmaceutical companies and a number of projects for different companies have been carried out. Currently, major pharmaceutical companies and contract research organizations in most European countries are among the customers of KinaseDetect.
Protein kinases are involved in the control of a large number of cellular processes and play a central role in human physiology. More than 500 genes encoding protein kinases have been identified in the human genome, and it is estimated that about 30% of all human proteins may be phosphorylated by kinases. During phosphorylation a phosphate group from an ATP molecule bound to a protein kinase is transferred to the target protein, resulting in the activation of a signalling cascade. This may in turn induce a series of cellular processes involving neurotransmitters, hormones and growth factors. Deficiency in kinase activity has implications in central nervous system disorders, cancer, autoimmune diseases and immunosuppression, diabetes, osteoporosis and various metabolic disorders. Kinase inhibitors are the largest class of new cancer drugs as reported in Knight et al, 2010. The first small molecule kinase inhibitor approved for use in humans was Imatinib, which has dramatically changed the prognosis for patients with chronic myeloid leukaemia. Many new protein kinases are being identified as potential targets for the treatment of cancer, diabetes and inflammation. According to recent report by Biophoenix (“Innovations in Protein Kinase Therapies”, May 2009), there are currently 608 kinase-targeting drugs under development by 232 originating companies. Of these 21 (3.5%) have been launched, and 28 (7.8%) are in Phase 3 clinical trials or beyond (and consequently approximately 90% are in early pharmaceutical development up to Phase 2 clinical trials). A total of 173 different drug targets are under investigation. By far the most popular indication is cancer (74.8%), followed by arthritis (9.4%), diabetes (5.8%), and inflammation (5.8%). Based on the examination of all kinase-targeting drug segments, the global market for kinase-targeted drugs is forecast to grow by 18% per annum from $13 billion in 2008 to $35 billion in 2013. Kinase-targeted drugs are estimated to account for approximately 6% of the total number of drugs currently in development (approximately 9400, according to IMS Health LifeCycle R&D Focus report).
KinaseDetect´s research focus is on protein kinase assay development and screening compound libraries in order to identify inhibitor compounds which interfere with kinase activity and can be used (i) for basic research in order to elucidate signal transduction pathways involved in disease processes and (ii) as starting point for development of new kinase inhibitors for treating diseases. KinaseDetect has world-class expertise in the field of recombinant protein kinase production and kinase assay development and has customers in all European countries, Israel, USA and Japan.